Sat, Oct 25, 2014, 1:47 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Talon Therapeutics, Inc. Message Board

  • perdooky perdooky Nov 14, 2012 1:00 PM Flag

    November 14th Conference Call Highlights

    CC Highlights (last 3 items from bhakes post):

    - Premium pricing strategy applies to Marqibo
    - Commercial launch of Marqibo in US in 2013 Q1
    - Efforts include the development of a comprehensive advertising and promotional campaign, that will debut in leading medical journals this month
    - 3 presentations at the 2012 American Society of Hematology Meeting (December 8-11, 2012) to highlight study data. Also, several booths.
    - As they had all efforts focused on the ODAC meeting this time last year, all efforts are focused on the ASH meeting and commercialization preparation. They expect similarly rewarding results.
    - There was significant effort and travel in the 3rd quarter related to the assessment of several varied strategic transaction opportunities
    - Assessing transactions that will augment Marqibo commercial launch, and help the Marqibo franchise reach its full medical and financial potential
    - It is more probably than not that Marqibo will be launched following a strategic transaction
    - Abundant and serious interest in an asset such as Marqibo stems from that it is already approved, thus de-risked, and ready to take to market. Also, that the Phase 3 trial is already up and running.
    - Menadione is currently in a Phase 2 study. Enrollment has recently accelerated, and no toxicity issues have been encountered. Data available in first half of 2013.
    - Talon currently evaluating different commercialization paths for Marqibo. From Merger & Acquisition (buyout) to licensing agreements (partner) to Talon launching Marqibo alone. The probability is greater for a strategic transaction than Talon launching it on its own
    - Just over 160+MM shares common & converted
    - There are 1700 patients (annually) in the US likely to use Marqibo for ALL
    - The company will submit an application for Marqibo use in Europe in the next year

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Digital River Inc.
NasdaqGSFri, Oct 24, 2014 4:00 PM EDT